PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
Mindray (300760 CH)
Awaiting domestic demand rebound
In 2024 Mindray reported revenue of RMB 367bn (51% YoY) and attributable
net profit of RMB 117bn (07% YoY) GPM dropped by 11 ppts YoY to 631%
primarily due to 1) pricing pressure on IVD reagents and mid- to low-end medical
equipment 2) weaker IVD testing demand following DRG 20 implementation
and inter-hospital recognition of test results The proportion of revenue from IVD
reagent declined in 4Q24 The Sino-US trade frictions may raise costs for US-
sourced raw materials in 2025E while Mindray is actively seeking substitutes to
protect margins In 1Q25 Mindrays revenue fell by 121% YoY to RMB82bn
mainly due to 1) over 20% YoY decline in domestic revenue as revenue
recognition lagged behind procurement recovery 2) a high overseas revenue
base in 1Q24 (up nearly 30% YoY) resulting in slow 1Q25 overseas growth of
 Steady growth from overseas In 2024 overseas revenue grew by 213%
YoY to RMB164bn accounting for 447% of total revenue (60ppts) Ex-
North America revenue rose 26% YoY to RMB138bn with Asia-Pacific
continuing as the growth engine Mindray achieved further breakthroughs in
high-end markets with high-end strategic customers contributing 14% of
overseas revenue With enhanced localization and installations of high-end
products such as the MT 8000 we expect the overseas revenue to grow by
a mid-teens percentage in 2025E As the US contributed only 6% of
Mindrays total revenue the impact of trade frictions may be moderate
Diversified manufacturing across 13 countries and proactive inventory
management should help mitigate related risks
 Domestic market remained under pressure In 2024 domestic revenue
decreased by 51% YoY to RMB203bn Revenue from PMLS and MIS
segments fell 31% YoY and 2% YoY respectively due to weak hospital
procurement According to IQVIA Chinas medical equipment market
decreased 123% YoY in 2024 Policy headwinds including DRG 20 inter-
hospital recognition of test results and reagent price cuts further weighed
on IVD revenue IQVIA estimated a decline in the biochemical market and
flat growth in immunology market in 2024 Therefore Mindrays domestic
IVD revenue increased 1% YoY in 2024 However Joinchain data shows a
675% YoY increase in medical equipment bidding value in 1Q25 indicating
potential recovery of domestic medical equipment procurement We
anticipate the revenue recovery will occur in 2H25E primarily due to the
time lag between the bidding process and revenue recognition
 Maintain BUY Given the uncertainties of the timeline of domestic
procurement recovery and trade frictions we revise down our earnings
forecasts We expect revenue and attributable net profit to grow 94% and
65% YoY respectively in 2025E Based on a 9-year DCF model we adjust
our TP to RMB24919 (WACC 92% terminal growth rate 30%)
(Previous TP
RMB32881)
UpDownside
Jill WU CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Smartco Development Limited
Magnifice (HK) Limited
Source SZSE
Source FactSet
12-mth Price Performance
Source FactSet
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Net profit (RMB mn)
YoY growth (%)
Adjusted net profit (RMB mn)
EPS (Adjusted) (RMB)
Net gearing (%)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
Sourceï¼šCompany data Bloomberg CMBIGM estimates
Figure 2 Risk-adjusted DCF valuation
DCF Valuation (in RMB mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
 of shares (mn)
DCF per share (in RMB)
Source CMBIGM estimates
Figure 3 Sensitivity analysis
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 4 CMBIGM estimates vs consensus
Source Company data Bloomberg CMBIGM estimate
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Gainloss on financial assets at FVTPL
Investment gainloss
Other gains(losses)
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Non-current assets
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
Net cash from operations
Acquisition of subsidiaries investments
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Adj net profit
Adj net profit margin
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Net debt to equity (x)
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
PE (diluted)
Div yield (%)
Source Company data CMBIGM estimates Note The calculation of net cash includes financial assets
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities or issuer
that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer and (2)
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures
Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report (2) will
deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve as an officer of any of the Hong
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the
report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM
or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIGM may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with
and CMBIGM will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified
as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules
intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing to
effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined
in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its
respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations
Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities
and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law
Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report